A detailed history of Black Rock Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,517,580 shares of ATXS stock, worth $33.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,517,580
Previous 3,585,493 1.89%
Holding current value
$33.6 Million
Previous $50.4 Million 36.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$8.83 - $13.51 $599,671 - $917,504
-67,913 Reduced 1.89%
3,517,580 $32 Million
Q1 2024

May 10, 2024

BUY
$6.99 - $16.69 $9.79 Million - $23.4 Million
1,400,935 Added 64.13%
3,585,493 $50.4 Million
Q4 2023

Feb 13, 2024

BUY
$4.42 - $8.06 $2.19 Million - $4 Million
495,722 Added 29.35%
2,184,558 $16.8 Million
Q3 2023

Nov 13, 2023

BUY
$6.89 - $9.86 $250,286 - $358,174
36,326 Added 2.2%
1,688,836 $12.6 Million
Q2 2023

Aug 11, 2023

BUY
$8.33 - $13.72 $11.4 Million - $18.7 Million
1,364,141 Added 473.05%
1,652,510 $13.8 Million
Q1 2023

May 12, 2023

BUY
$11.2 - $15.79 $2.2 Million - $3.11 Million
196,770 Added 214.82%
288,369 $3.84 Million
Q4 2022

Feb 13, 2023

BUY
$7.44 - $14.89 $98,758 - $197,649
13,274 Added 16.95%
91,599 $1.36 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $50,097 - $174,415
16,868 Added 27.45%
78,325 $708,000
Q2 2022

Aug 12, 2022

BUY
$2.46 - $6.96 $27,234 - $77,054
11,071 Added 21.97%
61,457 $185,000
Q1 2022

May 12, 2022

SELL
$3.92 - $7.1 $10,533 - $19,077
-2,687 Reduced 5.06%
50,386 $338,000
Q4 2021

Feb 10, 2022

BUY
$5.08 - $8.62 $60,741 - $103,069
11,957 Added 29.08%
53,073 $287,000
Q3 2021

Nov 09, 2021

BUY
$7.32 - $12.9 $300,969 - $530,396
41,116 New
41,116 $363,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $145M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.